Teflon and Pericardial Aortic Valve Prostheses

Bjoerk, V O; Hultquist, Gösta T.

doi:10.1016/s0022-5223(19)33497-x

Cited by 94 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Attempts to replace aortic valve cusp tissue with biologic material have been made since the late 1960s. [19][20][21] Fascia lata, dura mater, and bovine pericardium have been used in a small number of patients, but the results have not been favorable in the majority of instances. Halees and colleagues 4 reported that autologous pericardium and bovine pericardium did not show a difference in terms of structural valve deterioration with 16 years of follow-up of aortic valve reconstruction.…”

Section: Discussionmentioning

confidence: 99%

A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium

Ozaki

Kawase

Yamashita

et al. 2014

The Journal of Thoracic and Cardiovascular Surgery

198

154

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium

Ozaki

Kawase

Yamashita

et al. 2014

The Journal of Thoracic and Cardiovascular Surgery

198

154

View full text Add to dashboard Cite

show abstract

“…Fresh autologous pericardium tends to be an attractive option due to advantages such as immediate availability, low-cost, the absence of donor-derived pathogens and non-immunogenicity (4). It provides satisfactory long-term results when used for repair of simple congenital defects and for aortic valve repair when rapidly fixed with glutaraldehyde (5,14). However, when used without glutaraldehyde fixation, it shrinks, develops fibrosis and tends to stretch when exposed to high cardiovascular pressure, with reports of aneurysm formation at the site of the repair (13).…”

Section: Discussionmentioning

confidence: 99%

Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes

Neethling

Rea

Forster³

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

Background: A Phase II Clinical Trial reviewed the performance (morbidity and calcification) of the tissue-engineered ADAPT ® bovine pericardial scaffold (CardioCel ®) in pediatric patients (n = 30) with congenital cardiac defects. In that study, CardioCel ® demonstrated no graft-related morbidity and mortality in 25 patients, over 12 months. Five patients died due to non-graft-related events. Echocardiography revealed hemodynamically stable repairs with no calcification of the scaffold. Magnetic resonance imaging (MRI) at 12 months in 10 patients confirmed the absence of calcification. These patients were followed up for further up to 10 years. We present the results of this retrospective review of these patients that were followed for further medium to long-term (median 7.2 years, 25%: 3.6 years 75%: 9.25 years) postoperatively in these patients. Methods: Between April 2008 and September 2009, CardioCel ® was implanted in 30 patients with congenital cardiac defects. Efficacy measures included graft-related mortality, morbidity and haemodynamic abnormalities. Calcification was assessed by standard 2D-M mode echocardiography and MRI at 12 months. Medium to long-term assessment included routine clinical assessments and echocardiography. Results: Median age at surgery was 18 months (27 days−13 years). Twenty-five patients (142 patient years) were followed for up to 10 years. The 10-year survival rate is estimated as 86.9% (95% CI 71.4-100.0%) over the entire follow-up period. One patient was lost to follow-up. No graft-related mortality was encountered up to a median follow-up of 7.2 years. Two patients died (pacemaker complications >5 years and arrhythmia >7 years postoperatively). No graft failure, thromboembolic events, infections or device-related reinterventions were recorded. Non-significant residual leaks occurred in 3 patients. Echocardiography demonstrated the absence of calcification in all implants. Conclusion: The tissue-engineered ADAPT ® bovine pericardial scaffold demonstrated excellent medium to long-term performance (up to 10 years) when used as a scaffold for Neethling et al. Performance of CardioCel repair of congenital cardiac defects in children. Durability, acellularity, biostability and non-calcifying potential of CardioCel ® makes it a very attractive tissue for congenital cardiac repair procedures.

show abstract

“…4) Since the late 1960s, many kinds of biological materials have been used to replace the aortic valve cusp tissue. 10,11) The use of the pericardium in cardiovascular surgery and specifically as a material for aortic valve repair is not new. The results from a large number of reports in recent years have been highly variable.…”

Section: Discussionmentioning

confidence: 99%

Aortic Valve Replacement with Bovine Pericardium in Patients with Aortic Valve Regurgitation

et al. 2019

View full text Add to dashboard Cite

This study aimed to analyze the early and mid-term outcomes of aortic valve replacement with bovine pericardium in the treatment of aortic valve regurgitation. From January 2015 to March 2018, 36 patients (19 men; mean ± standard deviation [SD] age, 46.70 ± 16.60 years) underwent aortic valve replacement with bovine pericardium. The bovine pericardium was intraoperatively measured and shaped using an Ozaki template, according to the shape and size of the individual patient's aortic valve leaflets. Additional procedures were performed, including ventricular septal defect repair in 5 cases, mitral valve reconstruction in 6 cases, tricuspid valve reconstruction in 6 cases, and coronary artery bypass grafting in 3 cases. There were no perioperative deaths. One elderly patient with postoperative respiratory failure recovered after symptomatic treatment. One patient with frequent ventricular tachycardia after intraoperative cardiac re-jump underwent intra-aortic balloon counterpulsation (IABP), and the IABP device was successfully removed on the second postoperative day. Within the first 6 months of follow-up, there were no death events, no reoperation events, and no additional thromboembolic events. Follow-up echocardiography was performed for 6 months, with average left ventricular ejection fraction of 62.01 ± 3.21%, mean transvalvular pressure gradient of 11.17 ± 4.90 mmHg, and mean aortic valve velocity of 1.60 ± 0.58 m/s. Compared with the preoperative transthoracic echocardiography findings, the results at the six-month follow-up were statistically significant (P < 0.05). Mild aortic valve regurgitation occurred in 2 patients (5.56%), whereas other patients had no or only minimal aortic valve regurgitation (n = 34, 94.44%). Moderate aortic valve regurgitation occurred in one patient at 9 months after the initial operation. This was found to be due to infective endocarditis, and a biological valve was finally implanted. Aortic valve replacement with bovine pericardium in the treatment of aortic valve regurgitation is feasible, and good early and mid-term results are achieved. Long-term results need to be followed up in the future.

show abstract

Teflon and Pericardial Aortic Valve Prostheses

Cited by 94 publications

References 3 publications

A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium

A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium

Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes

Aortic Valve Replacement with Bovine Pericardium in Patients with Aortic Valve Regurgitation

Contact Info

Product

Resources

About